

UnitedHealthcare Community Plan Pharmacy & Therapeutics Committee Minutes

Meeting Date: September 12, 2024
 Location: Via conference call/Teams

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
Meeting called to order			5:01 PM EST	
A. Minutes from previous meetings		Review of Minutes from June 6, 2024	Minutes reviewed, approved	Yes
B. Mental Health Parity Training		Confirm Review of Mental Health Parity Training	MHP reviewed, completed	Yes
C. Formulary Review - New Drugs		Exxua	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Filsuvez	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Duvyzat	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Ojemda	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Pivya	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Opsynvi	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Winrevair	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Xolremdi	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Risvan	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Tryvio	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Acebutolol	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Voydeya	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
D. Formulary Review - PDL Modifications		Confirm Review of PDL Modifications Grid	Yes/No	Yes
		Recommendation: • Cimzia : Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Wegovy : Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Humira : Move to non-preferred with prior authorization in the NY EPP and NY CHIP markets only	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Buprenorphine/ Naloxone 4-1mg : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Buprenorphine/ Naloxone 12-3mg : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Esomeprazole : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Promacta 12.5mg packets : Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Fensolvi : Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Lupron Depot- Ped 45mg 6 month : Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Dimethyl Fumarate : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Teriflunomide : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Fingolimod Hydrochloride : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
E. Formulary Review - New Drugs- Medical		Confirm Review of New Drugs- Medical Grid	Yes/No	Yes
		Amtagvi		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Lenmeldy		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Alyglo		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Anktiva		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Beqvez		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Combogesic		
		Recommendation: • Medical benefit across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Comment: [REDACTED] asked about pricing. [REDACTED] responded, she will work with [REDACTED] to get some pricing.		
F. Formulary Review - Drugs Evaluated Per Grid		Apply recommendations as outlined in grid	Motion made, seconded, and carried to accept recommendation	10:0
G. Clinical Guidelines		Clinical Guideline Review		
		Apply New Pharmacy Guidelines	Motion made, seconded, and carried to accept recommendation	10:0
		Continue to Apply Pharmacy Guidelines Requiring Modifications	Motion made, seconded, and carried to accept recommendation	10:0
		Remove Pharmacy Guidelines Requiring Archival	Motion made, seconded, and carried to accept recommendation	10:0
		Comment: [REDACTED] asked about Spravato which is in the policy packet. What does the following mean, hard-coded with a quantity of 0.29/day for the 56mg strength and 0.43/day for the 84mg strength? [REDACTED] answered, this note is specific for a diagnosis of depressive symptoms with major depressive disorder, with acute suicidal behavior. This note is for our coding and authorization teams to provide instructions for this specific diagnosis since it will require a higher quantity than what is coded for the major depressive disorder (treatment-resistant) indication. [REDACTED] added, our quantity limit is set for the other indication, so this note is in place to make sure that if a patient is coming in for major depressive disorder with acute suicidal ideation, that they can get the authorization for the drug itself and the authorization for appropriate quantity, so that they don't receive a second rejection for quantity.		
H. Quality Monitoring		Confirm Review of Quality Data	Yes/No	Yes
		DUR Review		
		Comment: [REDACTED] asked, do you have a breakdown of the specialties for the prescribers for this? I am particularly interested in Gabapentin for this [REDACTED] replied, at this time we do not have breakdown of the specialties. We do get member level detail reports for these programs, and we do have information of who the providers are but it doesn't include provider specialty, only the provider's name and NPI.		
		Comment: [REDACTED] asked what other outcomes do you anticipate following? [REDACTED] responded, at this time these are the primary outcomes that we are following. OptumRx does provide some additional information related to pharmacy savings, but this time we are just looking how many recommendations were implemented and some of the savings' information. [REDACTED] would love to see it extrapolated over to the medical side, to see if there are any positive outcomes data. [REDACTED] will bring this request back to OptumRx.		
		Drug Recalls – 2nd Quarter 2024		
		Top 25 Drugs by Spend and Volume – 2nd Quarter 2024		
		Top 10 Drugs Requested - Approvals and Denials – 2nd Quarter 2024		
		Grievances and Appeals Data – 2nd Quarter 2024		
		Inter-Rater Reliability (IRR) – 2nd Quarter 2024		
		• Pharmacists		
Adjournment			6:53 PM EST	
Respectfully Submitted to the Committee,				
[REDACTED]				
[REDACTED]				
[REDACTED] UHC C&S				